http://www..ias2009.org

5th International AIDS Society Conference on HIV Pathogenesis and Treatment


Cape Town - July 19 - 22, 2009

VIROLOGIC FAILURE AND SECOND-LINE ANTIRETROVIRAL THERAPY (ART) IN CHILDREN IN SOUTH AFRICA: THE INTERNATIONAL EPIDEMIOLOGIC DATABASES TO EVALUATE AIDS (IeDEA) SOUTHERN AFRICA COLLABORATION

IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOAB104

M.-A. Davies 1, R. Wood2,3, G. Van Cutsem4,5, J. Giddy6, B. Eley7,8, H. Rabie9, H. Moultrie10,11, K. Technau10,12, A. Boulle1, International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA)
1University of Cape Town, Infectious Diseases Epidemiology Unit, School of Public Health and Family Medicine, Cape Town, South Africa, 2University of Cape Town, Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, Cape Town, South Africa, 3Gugulethu Community Health Centre, Cape Town, South Africa, 4Médecins Sans Frontières, Cape Town, South Africa, 5Khayelitsha Community Health Centre, Cape Town, South Africa, 6McCord Hospital, Durban, South Africa, 7University of Cape Town, School of Child and Adolescent Health, Cape Town, South Africa, 8Red Cross Children's Hospital, Cape Town, South Africa, 9University of Stellenbosch, Tygerberg Academic Hospital, Stellenbosch, South Africa, 10University of Witwatersrand, Paediatric HIV Clinics, Johannesburg, South Africa, 11Chris Hani Baragwanath Hospital, Harriet Shezi Clinic, Johannesburg, South Africa, 12Coronation Women and Children Hospital, Johannesburg, South Africa

BACKGROUND: As more children access ART, increasing numbers will experience treatment failure and require secondline. There is no single definition of virologic failure in children, and studies of failure and outcomes on second-line from resource-limited settings are lacking. We used data from IeDEA Southern Africa paediatric ART cohorts to examine:

METHODS: ART-naïve children (<16 years) initiating triple therapy at IeDEA Southern Africa sites with routine 6-monthly virologic monitoring were included. Virologic failure was defined as two consecutive viral loads >10000 copies/ml more than 5 months after ART start. Kaplan-Meier estimates of probability of failure as well as outcomes after switch were determined. Cox-proportional hazards models stratified by site were used to examine associations between baseline characteristics and failure.

RESULTS: Median (IQR) follow-up of 5484 children was 16 (6-29) months. Virologic failure occurred in 310 children and 146 were switched with cumulative probabilities of 11.4% (95%CI: 10.1-12.8) and 6.0% (95% CI: 5.0-7.2) at 3 years respectively. The median (IQR) interval between failure and switch was 4.8 (1.5-9.4) months.


Variable		 Number of children (%) Adjusted HR (95% CI)
Age <12 months 1158/5484 (21) 1.14 (0.76 - 1.71)
Viral load >1 million copies/ml 790/3745 (21) 1.88 (1.33 - 2.68)
Severe immune suppression (WHO definition) 3758/4576 (82) 2.01 (1.20 - 3.36)
WHO stage 3 or 4 2887/3832 (75) 1.40 (0.95 - 2.06)
Ritonavir used alone as third drug (vs Lopinavir/ritonavir or NNRTI) 382/5484 (7) 2.69 (1.72 - 4.20)

Survival and retention in care 1 year after switch were 97.1% (95%CI: 91.9-99.1) and 88.7% (95% CI: 81.7- 93.5) respectively with 55% being virologically suppressed.

CONCLUSIONS: Approximately 50% of children with virologic failure were not switched, with a notable delay between failure and switching. Ritonavir strongly independently predicts virologic failure.

Acrobat ReaderDownload PDF of this abstract.

Acrobat ReaderDownload PDF presentation.

2009-07-22
MOAB104
Oral Abstract Session MOAB1 - Paediatric ART: Successes and Challenges

Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.